Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M

Enveric Biosciences, Inc.

2025-Q1 EPS reported -$1.22

Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.
Out-licensing deals with Aries ($61M milestones), MycoMedica ($62M), Restoration Biologics ($82M).
Lead candidate EB-003 confirmed oral bioavailability and brain exposure; pre-IND activities ongoing.
Closed $5M public offering in 2024 to fund development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.